154105-64-3

Usage

Uses

Used in Organic Synthesis:
4-Bromopyridine-3-carboxaldehyde is utilized as a key intermediate in organic synthesis for the production of various chemical compounds. Its unique structure and reactivity make it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Bromopyridine-3-carboxaldehyde is used as an active pharmaceutical ingredient (API) intermediate. Its presence in the molecular structure of certain drugs contributes to their therapeutic effects. As an intermediate, it plays a crucial role in the development of new medications and the improvement of existing ones.
Used in Environmental Protection:
Although classified as harmful and dangerous for the environment, 4-Bromopyridine-3-carboxaldehyde can also be used in the development of environmental protection technologies. Its application may involve the creation of compounds that can help in pollution control or the development of eco-friendly products.

InChI:InChI=1/C6H4BrNO/c7-6-1-2-8-3-5(6)4-9/h1-4H

Upstream product

• 1120-87-2 4-bromopyridin 
• 68-12-2 N,N-dimethyl-formamide 
• 19524-06-2 4-bromopyridine hydrochloride 
• 2591-86-8 N-Formylpiperidine 
• 500-22-1 3-pyridinecarboxaldehyde 

Downstream Products

• 222167-67-1 4-Phenylethynyl-pyridine-3-carbaldehyde 
• 478149-07-4 methyl thieno[3,2-c]pyridine-2-carboxylate 
• 197007-88-8 4-bromo-3-pyridinemethanol benzyl ether 
• 1161865-21-9 4-phenylsulfonylpyridine-3-carbaldehyde 
• 1196699-67-8 methyl (2Z)-3-(4-bromo(3-pyridyl))-2-[(phenylmethoxy)carbonylamino]prop-2-enoate 
• 46268-56-8 4-phenyl-3-pyridinecarbaldehyde 
• 1491271-34-1 (4-phenylpyridin-3-yl)methanamine 
• 1053265-83-0 3-(Chloromethyl)-4-(4-chlorophenyl)pyridine 
• 1053265-80-7 [4-(4-Chlorophenyl)-3-pyridyl]methanol 

Relevant academic research and scientific papers

trans-2,6-, 3,6- And 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzophenanthrene-10,11-diols as dopamine agonists

The title compounds were synthesized by replacing the thiophene moiety of A-86929(2a) with variously substituted pyridines. Dopamine D-1 and D-2 binding and adenylate cyclase assays indicate that 4,6-diaza compounds 15 are potent and selective full D1 agonists when R1 is H or a small substituent and R2=H, with D1 binding affinity and adenylate cyclase functional potency equivalent to that of A-86929(2a).

One-pot homo- and cross-coupling of diazanaphthalenes via C-H substitution: Synthesis of Bis- and Tris-diazanaphthalenes

The transition metal-free coupling reactions of unactivated diazanaphthalenes were studied using only lithium tetramethylpiperidine (LiTMP) reagent. Symmetrical and nonsymmetrical bis-diazanaphthalenes were synthesized in moderate to high yield by homo- and cross-coupling of related monomers. In addition, the single-step synthesis of diquinoxalino [2,3-a: 2', 3'c] phenazine and 2,2': 3', 2″ - terquinoxaline using the appropriate equivalent amount of LiTMP was performed. The products were characterized by means of NMR spectroscopy and HRMS spectrometry.

Five-membered azole heterocyclic compound and its preparation method, pharmaceutical composition and use thereof

The present invention relates to a five-membered azole heterocycle compound represented by the following general formula (I), a preparation method of the five-membered azole heterocycle compound, a drug composition of the five-membered azole heterocycle compound, and a use of the five-membered azole heterocycle compound in preparation of drugs for prevention or treatment of TGR5-mediated diseases. The formula (I) is represented by the instruction.

NRF2 REGULATORS

Provided are aryl analogs，pharmaceutical compositions containing them and their use as NRF2 regulators.

ARYL ETHER-BASE KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Synthesis and σ receptor affinity of regioisomeric spirocyclic furopyridines

In order to investigate systematically the effect of the position of the pyridine N-atom on the σ1 receptor affinity four regioisomeric furopyridines 2a-d were synthesized and pharmacologically evaluated. The key steps of the synthesis comprise bromine/lithium exchange at regioisomeric bromopyridinecarbaldehyde acetals 7a-d, subsequent addition to 1-benzylpiperidin-4-one and cyclization. The regioisomeric acetals 7a-d were obtained either by o-metalation of bromopyridines 5b and 5c or by oxidation of bromopicolines 3a and 3d. In radioligand binding studies the regioisomeric furopyridines 2a-d showed 7- to 12-fold lower σ1 affinity than the benzofuran analog 1. The reduced σ1 affinity of the furopyridines 2a-d is explained with the reduced electron density of the pyridine ring. Since the four regioisomeric furopyridines show almost the same σ1 affinity (Ki = 4.9-10 nM), a directed interaction of the pyridine N-atom with the receptor protein can be excluded.

Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists

Given its role in the mediation of energy and glucose homeostasis, the G-protein-coupled bile acid receptor1 (TGR5) is considered a potential target for the treatment of type2 diabetes mellitus and other metabolic disorders. By thorough analysis of diverse structures of published TGR5 agonists, a hypothetical ligand-based pharmacophore model was built, and a new class of potent TGR5 agonists, based on the novel 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazole core, was discovered by rational design. Three distinct synthetic methods for constructing 4,5-dihydro-1,2,4-oxadiazoles and extensive structure-activity relationship studies are reported herein. Compound (R)-54n, the structure of which was determined by single-crystal X-ray diffraction and quantum chemical solid-state TDDFT-ECD calculations, showed the best potency, with an EC50 value of 1.4nM toward hTGR5. Its favorable properties invitro warrant further investigation.

Aryl Ether-Base Kinase Inhibitors

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Synthesis of 1-phenyl- and 1-pyridyl-3-pyridoazepines by reductive cyclization of diarylacetonitriles

Several pyrido[2,3-d]azepines and pyrido[3,4-d]azepines, novel aza analogs of the pharmacologically relevant 1-aryl-3-benzazepines, were synthesized by assembling the azepine ring by reductive cyclization of (2-methoxyvinyl)pyridinyl(aryl)acetonitrile derivatives, which were easily derived from contiguously substituted bromo(2-methoxyvinyl)pyridines and the corresponding arylacetonitriles.

Therapeutic Pyrazolyl Thienopyridines

The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.